Pancreatic Cancer Research

ResearcherMonash Medical CentreNo recent work listed

Marion Harris

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4420-1915; OpenAlex author ID A5086605611. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
60
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 3 papers

Papers 11

  1. ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenoc… Last author DOI 10.1016/j.esmogo.2023.07.001↗
  2. Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population. Co-author DOI 10.1111/ajco.13807↗
  3. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  4. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRI… Last author DOI 10.1016/j.esmoop.2021.100356↗
  5. KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation? Co-author DOI 10.3390/cells11193175↗
  6. EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy. First author DOI 10.3389/fonc.2021.770022↗
  7. The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial. Co-author DOI 10.4103/eus-d-20-00230↗
  8. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Co-author DOI 10.1093/annonc/mdz200↗
  9. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial. Last author DOI 10.1111/ajco.12999↗
  10. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Co-author DOI 10.1038/bjc.2016.185↗
  11. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. Co-author DOI 10.1056/nejmoa1304369↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel Gerald Croagh · 4 shared papers, 2021–2022 · strength 0.52
  2. Belinda Lee · 4 shared papers, 2019–2023 · strength 0.43
  3. Joanne Lundy · 3 shared papers, 2021–2022 · strength 0.39
  4. Brendan John Jenkins · 3 shared papers, 2021–2022 · strength 0.39
  5. Adnan M. Nagrial · 3 shared papers, 2019–2023 · strength 0.33
  6. Mehrdad Nikfarjam · 3 shared papers, 2019–2023 · strength 0.33
  7. Matthew Burge · 3 shared papers, 2019–2023 · strength 0.33
  8. Niall Christopher Tebbutt · 3 shared papers, 2019–2023 · strength 0.33
  9. Val Gebski · 2 shared papers, 2021–2023 · strength 0.25
  10. David Goldstein · 3 shared papers, 2016–2021 · strength 0.24
  11. John Raymond Zalcberg · 2 shared papers, 2021 · strength 0.22
  12. Benjamin N. J. Thomson · 2 shared papers, 2019–2023 · strength 0.20
  13. Prasad D. Cooray · 2 shared papers, 2019–2023 · strength 0.20
  14. Peter Gibbs · 2 shared papers, 2019–2023 · strength 0.20
  15. Henry Shen · 1 shared paper, 2022 · strength 0.16
  16. Adrian M. Fox · 1 shared paper, 2023 · strength 0.14
  17. Imogen Walpole · 1 shared paper, 2023 · strength 0.14
  18. Nam Quoc Nguyen · 1 shared paper, 2022 · strength 0.13
  19. Paul J. Ross · 1 shared paper, 2022 · strength 0.13
  20. Alain Hendlisz · 1 shared paper, 2022 · strength 0.13
  21. Thankamma Ajithkumar · 1 shared paper, 2022 · strength 0.13
  22. Harpreet Singh Wasan · 1 shared paper, 2022 · strength 0.13
  23. Alfredo Romano · 2 shared papers, 2016–2018 · strength 0.12
  24. Andrew Peter Dean · 1 shared paper, 2023 · strength 0.12
  25. Joanna Lee · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.